Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Environmental arsenic exposure and serum matrix metalloproteinase-9

Journal of Exposure Science & Environmental Epidemiology volume 23, pages 163–169 (2013)Cite this article

Subjects

Abstract

The objective of this study was to evaluate the relationship between environmental arsenic exposure and serum matrix metalloproteinase (MMP)-9, a biomarker associated with cardiovascular disease and cancer. In a cross-sectional study of residents of Arizona, USA (n=215) and Sonora, Mexico (n=163), drinking water was assayed for total arsenic, and daily drinking water arsenic intake was estimated. Urine was speciated for arsenic, and concentrations were adjusted for specific gravity. Serum was analyzed for MMP-9 using ELISA. Mixed model linear regression was used to assess the relation among drinking water arsenic concentration, drinking water arsenic intake, urinary arsenic sum of species (the sum of arsenite, arsenate, monomethylarsonic acid and dimethylarsinic acid), and MMP-9, controlling for autocorrelation within households. Drinking water arsenic concentration and intake were positively associated with MMP-9, both in crude analysis and after adjustment for gender, country/ethnicity, age, body mass index, current smoking, and diabetes. Urinary arsenic sum of species was positively associated with MMP-9 in multivariable analysis only. Using Akaike’s Information Criterion, arsenic concentration in drinking water provided a better fitting model of MMP-9 than either urinary arsenic or drinking water arsenic intake. In conclusion, arsenic exposure evaluated using all three exposure metrics was positively associated with MMP-9.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Wu MM, Kuo TL, Hwang YH, Chen CJ . Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am J Epidemiol 1989; 130 (6): 1123–1132.

    Article  CAS  Google Scholar 

  2. Chen CJ, Chiou HY, Chiang MH, Lin LJ, Tai TY . Dose-response relationship between ischemic heart disease mortality and long-term arsenic exposure. Arterioscler Thromb Vasc Biol 1996; 16 (4): 504–510.

    Article  CAS  Google Scholar 

  3. Lee MY, Bae ON, Chung SM, Kang KT, Lee JY, Chung JH . Enhancement of platelet aggregation and thrombus formation by arsenic in drinking water: a contributing factor to cardiovascular disease. Toxicol Appl Pharmacol 2002; 179 (2): 83–88.

    Article  CAS  Google Scholar 

  4. Bunderson M, Brooks DM, Walker DL, Rosenfeld ME, Coffin JD, Beall HD . Arsenic exposure exacerbates atherosclerotic plaque formation and increases nitrotyrosine and leukotriene biosynthesis. Toxicol Appl Pharmacol 2004; 201 (1): 32–39.

    Article  CAS  Google Scholar 

  5. Yuan C, Gao E, He B, Jiang G . Arsenic species and leaching characters in tea (Camellia sinensis). Food Chem Toxicol 2007; 45 (12): 2381–2389.

    Article  CAS  Google Scholar 

  6. Chiou HY, Hsueh YM, Liaw KF, Horng SF, Chiang MH, Pu YS et al Incidence of internal cancers and ingested inorganic arsenic: a seven-year follow-up study in Taiwan. Cancer Res 1995; 55 (6): 1296–1300.

    CAS  PubMed  Google Scholar 

  7. Hopenhayn-Rich C, Biggs ML, Smith AH . Lung and kidney cancer mortality associated with arsenic in drinking water in Cordoba, Argentina. Int J Epidemiol 1998; 27 (4): 561–569.

    Article  CAS  Google Scholar 

  8. Milton AH, Rahman M . Respiratory effects and arsenic contaminated well water in Bangladesh. Int J Environ Health Res 2002; 12 (2): 175–179.

    Article  CAS  Google Scholar 

  9. Parvez F, Chen Y, Brandt-Rauf PW, Slavkovich V, Islam T, Ahmed A et al A prospective study of respiratory symptoms associated with chronic arsenic exposure in Bangladesh: findings from the Health Effects of Arsenic Longitudinal Study (HEALS). Thorax 2010; 65 (6): 528–533.

    Article  Google Scholar 

  10. Dauphine DC, Ferreccio C, Guntur S, Yuan Y, Hammond SK, Balmes J et al Lung function in adults following in utero and childhood exposure to arsenic in drinking water: preliminary findings. Int Arch Occup Environ Health 2011; 84 (6): 591–600.

    Article  CAS  Google Scholar 

  11. Brown KG, Ross GL . Arsenic, drinking water, and health: a position paper of the American Council on Science and Health. Regul Toxicol Pharmacol 2002; 36 (2): 162–174.

    Article  CAS  Google Scholar 

  12. Meliker JR, Wahl RL, Cameron LL, Nriagu JO . Arsenic in drinking water and cerebrovascular disease, diabetes mellitus, and kidney disease in Michigan: a standardized mortality ratio analysis. Environ Health 2007; 6: 4.

    Article  Google Scholar 

  13. Ratnaike RN . Acute and chronic arsenic toxicity. Postgrad Med J 2003; 79 (933): 391–396.

    Article  CAS  Google Scholar 

  14. Mazumder DN . Effect of drinking arsenic contaminated water in children. Indian Pediatr 2007; 44 (2): 925–927.

    PubMed  Google Scholar 

  15. National Research Council . Arsenic in Drinking Water: 2001 Update. National Academy Press Washington, DC. 2001.

  16. Bardullas U, Limón-Pacheco JH, Giordano M, Carrizales L, Mendoza-Trejo MS, Rodríguez VM . Chronic low-level arsenic exposure causes gender-specific alterations in locomotor activity, dopaminergic systems, and thioredoxin expression in mice. Toxicol Appl Pharmacol 2009; 239 (2): 169–77.

    Article  CAS  Google Scholar 

  17. Meng X-Z, Zheng T-S, Chen X, Wang J-B, Zhang W-H, Pan S-H et al microRNA expression alteration after arsenic trioxide treatment in HepG-2 cells. J Gastroenterol Hepatol 2011; 26 (1): 186–193.

    Article  CAS  Google Scholar 

  18. Zarazúa S, Ríos R, Delgado JM, Santoyo ME, Ortiz-Pérez D, Jiménez-Capdeville ME . Decreased arginine methylation and myelin alterations in arsenic exposed rats. Neurotoxicology 2010; 31 (1): 94–100.

    Article  Google Scholar 

  19. Vahidnia A, van der Voet GB, de Wolff FA . Arsenic neurotoxicity—a review. Hum Exp Toxicol 2007; 26 (10): 823–32.

    Article  CAS  Google Scholar 

  20. Lantz RC, Lynch BJ, Boitano S, Poplin GS, Littau S, Burgess JL . Pulmonary biomarkers based on alterations in protein expression after exposure to arsenic. Environ Health Perspect 2007; 115 (4): 586–591.

    Article  CAS  Google Scholar 

  21. Olsen CE, Liguori AE, Zong Y, Lantz RC, Burgess JL, Boitano S . Arsenic upregulates MMP-9 and inhibits wound repair in human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2008; 295 (2): L293–302.

    Article  CAS  Google Scholar 

  22. Andrew AS, Jewell DA, Mason RA, Whitfield ML, Moore JH, Karagas MR . Drinking-water arsenic exposure modulates gene expression in human lymphocytes from a U.S. population. Environ Health Perspect 2008; 116 (4): 524–31.

    Article  CAS  Google Scholar 

  23. Chen CJ, Hsu LI, Wang CH, Shih WL, Hsu YH, Tseng MP et al Biomarkers of exposure, effect, and susceptibility of arsenic-induced health hazards in Taiwan. Toxicol Appl Pharmacol 2005; 206 (2): 198–206.

    Article  CAS  Google Scholar 

  24. Andrew AS, Burgess JL, Meza MM, Demidenko E, Waugh MG, Hamilton JW et al Arsenic exposure is associated with decreased DNA repair in vitro and in individuals exposed to drinking water arsenic. Environ Health Perspect 2006; 114: 1193–8.

    Article  CAS  Google Scholar 

  25. Kalela A, Koivu TA, Sisto T, Kanervisto J, Hoyhtya M, Sillanaukee P et al Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease. Scand J Clin Lab Invest 2002; 62 (5): 337–342.

    Article  CAS  Google Scholar 

  26. Ferroni P, Basili S, Martini F, Cardarello CM, Ceci F, Di Franco M et al Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation. J Investig Med 2003; 51 (5): 295–300.

    Article  CAS  Google Scholar 

  27. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH et al Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006; 113 (17): 2089–2096.

    Article  CAS  Google Scholar 

  28. Eldrup N, Gronholdt ML, Sillesen H, Nordestgaard BG . Elevated matrix metalloproteinase-9 associated with stroke or cardiovascular death in patients with carotid stenosis. Circulation 2006; 114 (17): 1847–1854.

    Article  CAS  Google Scholar 

  29. Sundstrom J, Vasan RS . Circulating biomarkers of extracellular matrix remodeling and risk of atherosclerotic events. Curr Opin Lipidol 2006; 17 (1): 45–53.

    Article  Google Scholar 

  30. Chen CJ, Chen CW, Wu MM, Kuo TL . Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br J Cancer 1992; 66: 888–892.

    Article  CAS  Google Scholar 

  31. Zucker S, Vacirca J . Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 2004; 23 (1,2): 101–117.

    Article  CAS  Google Scholar 

  32. Wu CY, Wu MS, Chiang EP, Chen YJ, Chen CJ, Chi NH et al Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution. Clin Cancer Res 2007; 13 (7): 2054–2060.

    Article  CAS  Google Scholar 

  33. Atkinson JJ, Senior RM . Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol 2003; 28 (1): 12–24.

    Article  CAS  Google Scholar 

  34. Ohbayashi H, Shimokata K . Matrix metalloproteinase-9 and airway remodeling in asthma. Curr Drug Targets Inflamm Allergy 2005; 4 (2): 177–181.

    Article  CAS  Google Scholar 

  35. Tayebjee MH, Lim HS, MacFadyen RJ, Lip GY . Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 in type 2 diabetes: effect of 1 year's cardiovascular risk reduction therapy. Diabetes Care 2004; 27 (8): 2049–2051.

    Article  CAS  Google Scholar 

  36. Jacqueminet S, Ben Abdesselam O, Chapman MJ, Nicolay N, Foglietti MJ, Grimaldi A et al Elevated circulating levels of matrix metalloproteinase-9 in type 1 diabetic patients with and without retinopathy. Clin Chim Acta 2006; 367 (1,2): 103–107.

    Article  CAS  Google Scholar 

  37. Josyula AB, Poplin GS, Kurzius-Spencer M, McClellen HE, Kopplin MJ, Sturup S et al Environmental arsenic exposure and sputum metalloproteinase concentrations. Environ Res 2006; 102: 283–290.

    Article  CAS  Google Scholar 

  38. Meza MM, Kopplin MJ, Burgess JL, Gandolfi AJ . Arsenic drinking water exposure and urinary excretion among adults in the Yaqui Valley, Sonora, Mexico. Environ Res 2004; 96 (2): 119–126.

    Article  CAS  Google Scholar 

  39. Roberge J, O'Rourke MK, Meza-Montenegro MM, Gutierrez-Millan LE, Burgess JL, Harris RB . Binational Arsenic Exposure Survey: methodology and exploration of the relationship between estimated arsenic intake from drinking water and urinary arsenic concentrations. Int J Environ Res Public Health 2012; 9: 1051–1067.

    Article  CAS  Google Scholar 

  40. Milstein LS, Essader A, Pellizzari ED, Fernando RA, Raymer JH, Levine KE, Akinbo O . Development and application of a robust speciation method for determination of six arsenic compounds present in human urine. Environ Health Perspect 2003; 111 (3): 293–296.

    Article  CAS  Google Scholar 

  41. Brown H, Prescott R . Normal Mixed Models. Applied Mixed Models in Medicine. John Wiley & Sons, Ltd. Chichester, England. 1999 pp. 33–51.

    Google Scholar 

  42. Achanzar WE, Brambila EM, Diwan BA, Webber MM, Waalkes MP . Inorganic arsenite-induced malignant transformation of human prostate epithelial cells. J Natl Cancer Inst 2002; 94 (24): 1888–1891.

    Article  CAS  Google Scholar 

  43. Cooper KL, Myers TA, Rosenberg M, Chavez M, Hudson LG . Roles of mitogen activated protein kinases and EGF receptor in arsenite-stimulated matrix metalloproteinase-9 production. Toxicol Appl Pharmacol 2004; 200 (3): 177–185.

    Article  CAS  Google Scholar 

  44. Hu Y, Jin X, Snow ET . Effect of arsenic on transcription factor AP-1 and NF-kappaB DNA binding activity and related gene expression. Toxicol Lett 2002; 133 (1): 33–45.

    Article  CAS  Google Scholar 

  45. Chanda S, Dasgupta UB, Guhamazumder D, Gupta M, Chaudhuri U, Lahiri S et al DNA hypermethylation of promoter of gene p53 and p16 in arsenic-exposed people with and without malignancy. Toxicol Sci 2006; 89 (2): 431–437.

    Article  CAS  Google Scholar 

  46. Galis ZS, Sukhova GK, Lark MW, Libby P . Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94 (6): 2493–2503.

    Article  CAS  Google Scholar 

  47. Yasmin, McEniery CM, Wallace S, Dakham Z, Pulsalkar P, Maki-Petaja K et al Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005; 25 (2): 372.

    Article  CAS  Google Scholar 

  48. Noji Y, Kajinami K, Kawashiri MA, Todo Y, Horita T, Nohara A et al Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med 2001; 39 (5): 380–384.

    Article  CAS  Google Scholar 

  49. Schonbeck U, Mach F, Libby P . Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol 1998; 161 (7): 3340–3346.

    CAS  PubMed  Google Scholar 

  50. Devaraj S, O'Keefe G, Jialal I . Defining the proinflammatory phenotype using high sensitive C-reactive protein levels as the biomarker. J Clin Endocrinol Metab 2005; 90 (8): 4549–4554.

    Article  CAS  Google Scholar 

  51. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K et al Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2 (10): 737–744.

    Article  CAS  Google Scholar 

  52. Rolli M, Fransvea E, Pilch J, Saven A, Felding-Habermann B . Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci USA 2003; 100 (16): 9482–9487.

    Article  CAS  Google Scholar 

  53. Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Niwa H et al Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res 2006; 26 (5A): 3579–3583.

    CAS  PubMed  Google Scholar 

  54. Yamanaka K, Hoshino M, Okamoto M, Sawamura R, Hasegawa A, Okada S . Induction of DNA damage by dimethylarsine, a metabolite of inorganic arsenics, is for the major part likely due to its peroxyl radical. Biochem Biophys Res Commun 1990; 168 (1): 58–64.

    Article  CAS  Google Scholar 

  55. Zhao CQ, Young MR, Diwan BA, Coogan TP, Waalkes MP . Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc Natl Acad Sci USA 1997; 94 (20): 10907–10912.

    Article  CAS  Google Scholar 

  56. Liu J, Liu Y, Goyer RA, Achanzar W, Waalkes MP . Metallothionein-I/II null mice are more sensitive than wild-type mice to the hepatotoxic and nephrotoxic effects of chronic oral or injected inorganic arsenicals. Toxicol Sci 2000; 55 (2): 460–467.

    Article  CAS  Google Scholar 

  57. Calderon RL, Hudgens E, Le XC, Schreinemachers D, Thomas DJ . Excretion of arsenic in urine as a function of exposure to arsenic in drinking water. Environ Health Perspect 1999; 107 (8): 663–667.

    Article  CAS  Google Scholar 

  58. Suzuki KT, Mandal BK, Ogra Y . Speciation of arsenic in body fluids. Talanta 2002; 58 (1): 111–119.

    Article  CAS  Google Scholar 

  59. Hughes MF . Biomarkers of exposure: a case study with inorganic arsenic. Environ Health Perspect 2006; 114 (11): 1790–1796.

    Article  CAS  Google Scholar 

  60. Pellizzari ED, Clayton CA . Assessing the measurement precision of various arsenic forms and arsenic exposure in the National Human Exposure Assessment Survey (NHEXAS). Environ Health Perspect 2006; 114 (2): 220–227.

    Article  CAS  Google Scholar 

  61. Rivera-Nunez Z, Meliker JR, Linder AM, Nriagu JO . Reliability of spot urine samples in assessing arsenic exposure. Int J Hyg Environ Health 2010; 213 (4): 259–264.

    Article  CAS  Google Scholar 

  62. Hu P, Greendale GA, Palla SL, Reboussin BA, Herrington DM, Barrett-Connor E et al The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: the postmenopausal estrogen progestin intervention (PEPI) trial. Atherosclerosis 2006; 185 (2): 347–352.

    Article  CAS  Google Scholar 

  63. Niessner A, Richter B, Penka M, Steiner S, Strasser B, Ziegler S et al Endurance training reduces circulating inflammatory markers in persons at risk of coronary events: impact on plaque stabilization? Atherosclerosis 2006; 186 (1): 160–165.

    Article  CAS  Google Scholar 

  64. Barbosa F, Gerlach RF, Tanus-Santos JE . Matrix metalloproteinase-9 activity in plasma correlates with plasma and whole blood lead concentrations. Basic Clin Pharmacol Toxicol 2006; 98 (6): 559–564.

    Article  CAS  Google Scholar 

  65. Laimer M, Kaser S, Kranebitter M, Sandhofer A, Muhlmann G, Schwelberger H et al Effect of pronounced weight loss on the nontraditional cardiovascular risk marker matrix metalloproteinase-9 in middle-aged morbidly obese women. Int J Obes (Lond) 2005; 29 (5): 498–501.

    Article  CAS  Google Scholar 

  66. Sillanaukee P, Kalela A, Seppa K, Hoyhtya M, Nikkari ST . Matrix metalloproteinase-9 is elevated in serum of alcohol abusers. Eur J Clin Invest 2002; 32 (4): 225–229.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This project was supported by NIEHS Grant ES06694 to the Southwest Environmental Health Sciences Center and NIH/NCI University of Arizona Specialized Program of Research Excellence (SPORE) in GI Cancer No.CA95060. Human subjects’ approval for this project was received from The University of Arizona Office for the Responsible Conduct of Research and Institutional Review Board.

Author information

Authors and Affiliations

  1. Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA

    Jefferey L Burgess, Margaret Kurzius-Spencer, Mary Kay O'Rourke, Sally R Littau, Jason Roberge & Robin B Harris

  2. Institute Technological of Sonora, Ciudad Obregon, Mexico

    Maria Mercedes Meza-Montenegro

  3. Department of Scientific and Technological Research, Universidad de Sonora, Hermosillo, Sonora, Mexico

    Luis Enrique Gutiérrez-Millán

Authors
  1. Jefferey L Burgess
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Margaret Kurzius-Spencer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mary Kay O'Rourke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sally R Littau
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jason Roberge
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maria Mercedes Meza-Montenegro
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Luis Enrique Gutiérrez-Millán
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Robin B Harris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jefferey L Burgess.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Burgess, J., Kurzius-Spencer, M., O'Rourke, M. et al. Environmental arsenic exposure and serum matrix metalloproteinase-9. J Expo Sci Environ Epidemiol 23, 163–169 (2013). https://doi.org/10.1038/jes.2012.107

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jes.2012.107

Keywords

This article is cited by

Search

Advanced search

Quick links